BIRC2 and B-cell non-Hodgkin lymphoma: TRAF3-TRAF2-BIRC2-BIRC3-MAP3K14 are mutated in 30% of all B-cell lymphomas, and 50% of all Cs B-cell lymphomas, which is about the same fraction as human DLBCL tumors with dysregulated canonical or noncanonical NF-κB pathways (Compagno et al. 2009).